NCIt definition : A bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial
growth factor A (VEGF-A), with potential anti-angiogenic and antineoplastic activities.
Upon administration, tovecimig simultaneously targets, binds to and blocks DLL4 and
VEGF-A. This prevents the activation of DLL-4/Notch- and VEGF-A/VEGF receptor (VEGFR)-mediated
signaling pathways, which play key roles in angiogenesis and tumor vascularization.
This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch
receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain
(NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional
regulation of a variety of genes involved in vascular development. The expression
of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is
required for the development of functional tumor blood vessels. VEGF-A is upregulated
in a variety of cancer cell types and plays a crucial role in angiogenesis.;
UNII : YXM6C5LQ2H;
CAS number : 2923284-73-3;
Molecule name : ES-104; CTX 009; ES 104; CTX-009; ABL 001; TR 009; ABL-001; NOV1501;